We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Techlab

TECHLAB, Inc. develops, manufactures, and distributes rapid non-invasive intestinal diagnostics in the areas of intes... read more Featured Products: More products

Download Mobile App





Techlab Showcases Range of Rapid, Non-Invasive Intestinal and Infectious Disease Diagnostic Products

By LabMedica International staff writers
Posted on 29 Sep 2021

TechLab Inc. More...

(Blacksburg, VA, USA) showcased its range of rapid, non-invasive intestinal and infectious disease diagnostic products at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

The AACC Annual Scientific Meeting & Clinical Lab Expo is the largest global scientific conference and tradeshow in the field of laboratory medicine. TechLab develops, manufactures, and distributes rapid non-invasive intestinal diagnostics in the areas of intestinal inflammation, antibiotic associated diarrhea and parasitology. The company manufactures a variety of in vitro diagnostics for enteric diseases to help determine whether a patient has a disease caused by Helicobacter pylori, Clostridium difficile, protozoan parasites, foodborne illness, or IBD/IBS.

At AACC 2021, TechLab demonstrated its diagnostic tests for C. difficile, parasitology, intestinal inflammation, Shiga toxins and Campylobacter. TechLab showcased its TRI-COMBO PARASITE SCREEN test which is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. The test is indicated for use as a screen for fecal specimens from patients with gastrointestinal illness including dysentery to aid in the diagnosis of enteric infection resulting from giardiasis, cryptosporidiosis or amebiasis. The TRI-COMBO PARASITE SCREEN test serves as a screen to rule out negative specimens and reduce the number of specimens that require additional follow-up testing. The test uses monoclonal and polyclonal antibodies to cell-surface antigens of Giardia, Cryptosporidium, and E. histolytica.

TechLab also highlighted the E. HISTOLYTICA QUIK CHEK test which is a rapid membrane enzyme immunoassay for the qualitative detection of adhesin from Entamoeba histolytica in a single use cassette. It is intended for use with human fecal specimens from patients with diarrhea or dysentery as an aid in the diagnosis of E. histolytica gastrointestinal infection. Also on display was the company’s GIARDIA/CRYPTOSPORIDIUM QUIK CHEK test which is a rapid membrane enzyme immunoassay for the simultaneous qualitative detection and differentiation of Giardia cyst antigen and Cryptosporidium oocyst antigen in a single test device. It is intended for use with human fecal specimens from patients with gastrointestinal symptoms to aid in the diagnosis of Giardia and/or Cryptosporidium gastrointestinal infection.

In addition, TechLab presented its C. DIFF QUIK CHEK COMPLETE test which is a rapid membrane enzyme immunoassay for the simultaneous detection of Clostridium difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well. The test is to be used as an aid in the diagnosis of C. difficile disease. The company also exhibited its SHIGA TOXIN QUIK CHEK test which is a rapid membrane enzyme immunoassay for the simultaneous qualitative detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test device. It is intended for use with human fecal samples from patients with gastrointestinal symptoms to aid in the diagnosis of disease caused by Shiga toxin producing Escherichia coli (STEC). It may be used with fecal specimens, or broth or plate cultures derived from fecal specimens.

Related Links:
TechLab Inc. 


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.